Written question asked by Chris Green (Conservative) on Monday, 16 October 2023, in the House of Commons. It was due for an answer on Wednesday, 18 October 2023. It was answered by Will Quince (Conservative) on Friday, 20 October 2023 on behalf of the Department of Health and Social Care.
Rare Diseases: Drugs
- Question
-
To ask the Secretary of State for Health and Social Care, how many highly specialised technology evaluations of medicines for very rare diseases conducted by the National Institute for Health and Care Excellence resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2018-19.
- Answer
-
The following table shows a breakdown of technologies appraised through the National Institute for Health and Care Excellence’s highly specialised technology process by financial year from 2018/19:
Financial Year
2018/19
2019/20
2020/21
2021/22
2022/23
Total
Recommended
1
4
2
4
4
15
Optimised
0
0
0
0
1
1
Not recommended
0
0
0
0
0
0
Total
1
4
2
4
5
16
Terminated
0
0
0
0
0
0
Secondary information
- Type
- Written question
- Reference
- 202780
- Session
- 2022-23
- Subjects
- Drugs National Institute for Health and Care Excellence Rare diseases
- Contains statistics
- Yes
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-10-20 13:13:20 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/202780
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/202780
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/202780